Prognostic factors related to recurrence after low- dose tacrolimus treatment in patients with myasthenia gravis

VernacularTitle:小剂量他克莫司治疗重症肌无力复发影响因素分析
Author: Xiaoyong TAO ¹ ; Wei WANG ; Zhongkui WANG ; Feng JING ; Wei HUANG ; Xiaofei GENG
Author Information

1. 解放军第三○九医院神经内科
Keywords: Myasthenia gravis; Recurrence; Tacrolimus
From: Chinese Journal of Postgraduates of Medicine 2018;41(9):823-825
CountryChina
Language:Chinese
Abstract: Objective To identify the 2- year recurrence- related factors in patients with myasthenia gravis (MG) after treatment of low-dose tacrolimus. Methods The clinical data of 100 MG patients treated with low- dose tacrolimus from February 2011 to February 2016 were retrospectively analyzed. All patients were followed up at least 2 years, and the risk factors affecting the recurrence of MG patients were analyzed. Results At the end of follow-up, there were 49 cases who had recurrence, and the recurrence rate was 44.5％ (49 / 110). Logistic regression analysis result showed that reducing dosage or withdrawal, MG crisis and diabetes mellitus were the independent risk factors for recurrence of MG patients (OR = 134.113, 8.850 and 6.652; P < 0.01 or <0.05). Conclusions The rate of recurrence with low- dose tacrolimus treatment in patients with MG during 2 years is higher. Reducing dosage or withdrawal should be avoided, especially in patients with a history of MG crisis. Patients with diabetics mellitus need to control blood glucose stability to avoid recurrence.